

Horizon Pharma plc  
Form 4  
September 22, 2014

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Walbert Timothy P

(Last) (First) (Middle)

C/O HORIZON PHARMA  
PLC, ADELAIDE CHAMBERS,  
PETER STREET

(Street)

DUBLIN, L2 8

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
Horizon Pharma plc [HZNP]

3. Date of Earliest Transaction  
(Month/Day/Year)  
09/19/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chairman, President and CEO

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code V Amount (A) or (D) Price			
Ordinary Shares	09/19/2014		A <sup>(1)</sup>	164,060 A	164,060	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: Horizon Pharma plc - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount of Number of Shares
Stock Option (Right to Buy)	\$ 10.43	09/19/2014		A <sup>(1)</sup>		121,701		<u>(2)</u>	07/15/2018	Ordinary Shares	121,701
Stock Option (Right to Buy)	\$ 5.2	09/19/2014		A <sup>(1)</sup>		128,937		<u>(2)</u>	02/02/2020	Ordinary Shares	128,937
Stock Option (Right to Buy)	\$ 12.94	09/19/2014		A <sup>(1)</sup>		112,787		<u>(2)</u>	06/15/2020	Ordinary Shares	112,787
Stock Option (Right to Buy)	\$ 4.96	09/19/2014		A <sup>(1)</sup>		216,955		<u>(4)</u>	12/07/2021	Ordinary Shares	216,955
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <sup>(1)</sup>		66,421		<u>(6)</u>	<u>(5)</u>	Ordinary Shares	66,421
Stock Option (Right to Buy)	\$ 2.4	09/19/2014		A <sup>(1)</sup>		147,000		<u>(4)</u>	01/01/2023	Ordinary Shares	147,000
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <sup>(1)</sup>		96,525		<u>(6)</u>	<u>(5)</u>	Ordinary Shares	96,525
Stock Option (Right to Buy)	\$ 7.61	09/19/2014		A <sup>(1)</sup>		223,000		<u>(4)</u>	01/01/2024	Ordinary Shares	223,000
Restricted Stock Units	<u>(5)</u>	09/19/2014		A <sup>(1)</sup>		198,000		<u>(6)</u>	<u>(5)</u>	Ordinary Shares	198,000

